Video accurate during time of recording, Eisai address has been updated.
For questions about HALAVEN, e-mail Eisai Medical Information at Esi_oncmedinfo@eisai.com or call 1.888.274.2378
References: 1. Cortes J, O'Shauhnessy J, Loesch D, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923. 2. Data on file, Eisai Inc.